NCT02932007 Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
| NCT ID | NCT02932007 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of South Florida |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2017-03-28 |
| Primary Completion | 2020-03 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years and older 2. History of symptomatic persistent AF Persistent AF - defined as continuous AF that is sustained more than 7 days but less than 12 months. Episodes of AF of ≥ 48 hours duration in which a decision is made to terminate with electrical or pharmacological cardioversion prior to 7 days will also be classified as persistent AF 3. AF must be documented at least once either by ECG, event monitoring, loop recorder, telemetry, trans-telephonic monitoring, pacemaker or cardiac defibrillator readouts within 24 months prior to enrollment 4. Currently on anticoagulation therapy as indicated per local guidelines, which is considered optimal for stroke prevention in the opinion of the investigator 5. Implanted dual chamber pacemaker/ICD capable of monitoring atrial arrhythmias or willingness to wear a 2 weeks event monitor if patient does not have a device capable of monitoring atrial arrhythmias 6. Signed informed consent Exclusion Criteria: 1. Age \<
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.